Arrowhead price target lowered to $78 from $81 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Arrowhead (ARWR) to $78 from $81 and keeps an Equal Weight rating on the shares. Broad pipeline execution continues with multiple readouts expected later this year, including key Phase 3 SHTG data in Q3, the analyst tells investors in a research note. the firm added that while early familial chylomicronemia syndrome launch trends are promising, meaningful sales are not expected in 2026.